Celgene’s Otezla Gets Preliminary Nod From NICE At Second Attempt
Executive Summary
Celgene’s near-blockbuster oral psoriasis drug Otezla is cleared by NICE in a second draft guidance for use in severe psoriasis, after the company comes up with an acceptable patient access scheme.
You may also be interested in...
Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.
Japan Grants Global First Nod For Brodalumab, For Psoriasis
Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibodies for the disorder in a new batch of approvals that also includes Praluent and Kyprolis.
Novartis and Celgene get EU approval for novel psoriasis therapies
The European Commission has approved two new drugs for psoriasis: Novartis's Cosentyx (secukinumab) and Celgene's Otezla (apremilast).